Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$7.41 -0.00%

-$0.00 today

Market cap
$933.77M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 2.87M

Average 2.58M

Big Five Numbers

Verastem, Inc. growth analysis

Start with the long-run numbers that show whether VSTM compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A+128.4%+209.1%
Equity
N/AN/A-34.5%N/A
Cash
N/AN/A+39.9%+130.8%
ROIC
N/A-99.6%-110.7%-97.4%

Analysis

Latest growth is strongest in Revenue at +209.1% and weakest in ROIC at -97.4%. Three-year average ROIC is -110.7%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/A+128.4%
+78.3% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +128.4% over three years. Forward estimates point to Revenue at +78.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where VSTM earns its revenue, as reported in company filings

  • Government rebates and other incentives
  • Trade discounts and allowances
  • Returns
  • Sale of COPIKTRA license and related assets
  • Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees
  • Copiktra license and related assets
  • Other
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
Government rebates and other incentives$4.39M77.7%—
Trade discounts and allowances$888K15.7%—
Returns$376K6.6%—

Figures in USD. Segments account for 18.3% of reported FY2025 revenue; $25.26M is not attributed to a segment. Smaller segments are grouped as "Other".

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$209.5M
+ D&A$728.0K
+ Stock-Based Comp$9.4M
+ Deferred Tax$0
+ Working Capital$26.0M
+ Other Non-Cash$35.8M
= Operating Cash Flow-$137.5M
- Capex$0
= Free Cash Flow-$137.5M

Analysis

FY2025 free cash flow is -$137.5M. FCF conversion is 65.6% of net income. Operating cash flow was -$137.5M, with capex of $0. The largest bridge item is Other Non-Cash at $35.8M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for VSTM.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for VSTM.

Sign in free

Competitor growth

How does Verastem, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Nuvation Bio Inc.

NUVB

$1.40B———
+64.1% (5yr)5 analysts

ORIC Pharmaceuticals, Inc.

ORIC

$814.71M———
—4 analysts

Adlai Nortye Ltd.

ANL

$563.18M———
+37.0% (5yr)2 analysts

C4 Therapeutics, Inc.

CCCC

$362.43M—+1.6%+5.0%
+135.8% (5yr)5 analysts

Prelude Therapeutics Incorporated

PRLD

$275.32M———
+52.5% (5yr)1 analysts

Immuneering Corporation

IMRX

$240.27M———
—5 analysts

BridgeBio Oncology Therapeutics Inc.

BBOT

$171.74M———
—6 analysts

Foghorn Therapeutics Inc.

FHTX

$124.12M—+135.1%+17.1%
+21.4% (5yr)3 analysts

Acrivon Therapeutics, Inc. Common Stock

ACRV

$62.14M———
—2 analysts

Cardiff Oncology, Inc.

CRDF

$56.49M+6.6%+10.1%+15.4%
+249.6% (5yr)2 analysts

Questions

Growth questions

Common questions about VSTM's growth, answered from reported and forecast figures.

Is VSTM growing revenue?

Revenue grew 209.1% year over year, from $10.00M to $30.91M.

Is VSTM turning growth into profit?

The latest net margin is -677.6%, which shows how much revenue became net income.